

## Essai Clinique Généré le 05 mai 2024 à partir de

Titre	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer
Protocole ID	CRC.9 (COBRA)
ClinicalTrials.gov ID	NCT04068103
Type(s) de cancer	Côlon et rectum
Phase	Phase II-III
Type étude	Clinique
Institution	CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL H HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville	
Investigateur principal	Dr Petr Kavan
Coordonnateur	Asma Akkari 514-340-8222 poste 24552
Statut	Fermé
But étude	This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Critères d'éligibilité	
Critères d'exclusion	